Author: Ravi Shankar

[Ad hoc announcement pursuant to Art. 53 LR]

This press release is also available in Français (pdf) and Deutsch (pdf)

Follow today’s event live
09:30 CEST Investor & analyst call – audio webcast
Full details on our website

………….

Third-quarter and nine-month 2026 sales

Sustained RIG improvement

Philipp Navratil, Nestlé CEO commented: “Our execution is driving stronger growth. RIG was positive across all zones and globally managed businesses and reached 2.8% in the third quarter, continuing the performance improvement of recent quarters. The agreement to divest our mainstream vitamins, minerals and supplements business marks another important step in focusing our portfolio where we have the strongest competitive advantage. Against a challenging external backdrop, our focus remains on delivering value, consistently executing with discipline and driving sustainable RIG-led growth across the business”.

Sales performance summary

	Total Group	Zone Americas	Zone Asia, Oceania and Africa	Zone Europe	Nespresso	Nestlé Waters & Premium Beverages	Other businesses
Sales Q3-2026 (CHF m)	22 756	10 088	5 340	4 680	1 593	1 033	22
Sales Q3-2025 (CHF m)	21 641	9 473	5 008	4 622	1 534	932	72
Real internal growth (RIG)	2.8%	2.4%	5.0%	1.0%	1.1%	7.3%	– 18.7%
Pricing	1.1%	1.0%	1.3%	0.2%	1.4%	5.0%	0.9%
Organic growth	4.0%	3.3%	6.4%	1.2%	2.5%	12.3%	– 17.8%

 

Financial highlights

• Focus on execution driving strong RIG; on track for mid-term target of sustainable 2%+ RIG
• 9M-26 organic growth (OG) of 3.7%, with real internal growth (RIG) of 1.9% and pricing of 1.8%.
• Q3-26 OG of 4.0%, with RIG improving to 2.8% and pricing of 1.1%, moderating as expected.
• Q3-26 RIG positive across all zones and globally managed businesses.

 

• Strong emerging markets growth; improving momentum in developed markets
• Emerging markets continued to deliver strong growth, with OG of 6.8% and RIG of 4.3% in Q3, while developed markets remained solid with OG of 2.2%.
• OG rebounded in North America, as Petcare sell-in matched strong sell-out and Coffee RIG improved following the price increases earlier in the year.
• In Europe, RIG recovered after the impact of Q2-26 de-listings, while pricing moderated further in a competitive environment.

Operational and strategic updates

• Good progress in executing our strategy
• Investment prioritization behind high growth platforms and execution focus in the core is driving results – growth platforms maintained high single-digit OG and core improved further in Q3.
• Further portfolio sharpening with agreement to divest the mainstream Vitamins, Minerals and Supplements (VMS) business for USD 1.0 billion announced in September.
• Ongoing steps to strengthen supply chain resilience and support long-term business performance, reflected in updated strategy on Climate & Nature and Packaging Sustainability.

 

• Update on Nestlé’s business in Russia
• Nestlé’s business in the Russian Federation no longer consolidated, effective end of September 2026, following placement under temporary external administration.
• No impact on Q3 or 9M sales, limited financial impact on 2026 underlying results.

 

2026 guidance maintained

• OG expected to be in the range of 3% to 4%, with RIG accelerating versus 2025, driven by our focused growth plans.
• Underlying trading operating profit (UTOP) margin expected to improve versus 2025; second half margin expected to be broadly similar to the first half, excluding any tariff refunds.
• Free cash flow expected to be above CHF 9 billion.

 

Follow today’s event live
09:30 CEST Investor & analyst call – audio webcast
Full details in Events

PDF press releases:

• English (pdf, 327Kb)
• Français (pdf, 361Kb)
• Deutsch (pdf, 332Kb)

Contacts:

Media:
Christoph Meier  Tel.: +41 21 924 2200
mediarelations@nestle.com

Investors:
David Hancock  Tel.: +41 21 924 3509
ir@nestle.com 
 

Financial review Q3 2026

Group

Total reported sales in Q3-26 were CHF 22.8 billion. Organic growth was 4.0%, comprising 2.8% RIG and 1.1% pricing. RIG was positive across all zones and globally managed businesses, with particularly strong performance in emerging markets. Pricing reflected the carryover of pricing actions in 2025, supported by incremental pricing in 2026. Foreign exchange movements had a positive impact of 1.5%.

By product category, Q3-26 growth was led by Petcare and Food & Snacks. Coffee OG was 3.4% as we lapped the strongest quarterly growth rate of 2025; on a two-year cumulative basis, OG in Q3 was similar to Q1 and Q2. In the US, Coffee RIG recovered progressively from the initial impact of price increases taken earlier in the year. Petcare OG was 5.3%, with strong RIG of 4.3%, driven by continued momentum in cat and with sell-in matching strong sell-out. Nutrition OG was 0.3%, as strength in medical nutrition was offset by softer performance in adult and kids & all family nutrition. The impact of the infant formula recall on group OG was 20 bps in the quarter. Food & Snacks OG was 5.0%, supported by strong performance in Americas confectionery and improving trends in US frozen foods, further helped by seasonal order phasing.

By geography, Q3-26 OG in developed markets was 2.2%, with RIG of 1.9% and pricing of 0.3%. In emerging markets, OG was 6.8%, with RIG of 4.3% and pricing of 2.5%.

By channel, Q3-26 OG in retail sales was 3.9% and in out-of-home (OOH) channels was 4.8%. Within retail, e-commerce had OG of 15.3% in Q3 and reached 21.6% of year-to-date Group sales.

Acquisitions and divestures

On 1 September 2026, Nestlé reached an agreement to divest its mainstream vitamins, minerals and supplements (VMS) business to Yellow Wood Partners for USD 1.0 billion (CHF 0.8 billion). The transaction is subject to regulatory approvals and is expected to close by the first half of 2027. The scope of the transaction comprises seven established brands (Nature’s Bounty, Osteo Bi-Flex, Ester-C, Gard, Nuun, Puritan’s Pride and Sisu), together with the associated US private-label supplements business, dedicated manufacturing, packaging, warehousing and distribution operations. In 2025, the business generated sales of USD 1.2 billion (CHF 1.0 billion). It predominantly operates in the US, with a presence in numerous other countries including Canada and China.

Nestlé’s operations in Russia

Following a Russian presidential decree published in September 2026, Nestlé’s operations in the Russian Federation (“Russia”) have been placed under temporary external administration. The Group remains the legal owner of the assets. As we currently do not have control of the management of the operations in Russia, from the end of September 2026, the business is no longer being consolidated by Nestlé S.A.

On an annualized basis, Nestlé’s operations in Russia contributed approximately 2% of Group sales and 3-4% of Group UTOP and free cash flow. On deconsolidation, net assets of approximately CHF 1.6 billion have been derecognized. In addition, the Group has recognized a charge of approximately CHF 1.4 billion in respect of cumulative currency translation adjustments, which is non-cash and will have no impact on the Group’s total equity. In total, the deconsolidation adversely impacts Group net debt by approximately CHF 0.9 billion for year-end 2026.

 

Operating segments

In this section, “growth” refers to organic sales growth, unless otherwise specified.
 

Zone Americas

9M-26 operating performance

• OG was 3.3%, with RIG of 1.5% and pricing of 1.8%.
• Reported sales were CHF 28.7 billion, with a negative impact of 3.1% from foreign exchange movements.

Q3-26 sales performance
In Zone Americas, growth was broad based with positive OG across all major markets, led by RIG. In the US, OG and RIG accelerated as continued execution focus and targeted investments drove improved performance, despite ongoing weakness in some consumer segments. In Latin America, continued RIG-led growth was broad based across markets and categories, supported by positive market momentum.

• OG was 3.3%, with RIG of 2.4% and pricing of 1.0%.
• North America OG was 2.6%, with 1.8% RIG and 0.8% pricing. In Latin America, OG was 5.2%, with 3.7% RIG and 1.5% pricing.
• For the Zone, the acceleration in OG and RIG was driven by the US and Canada, with stronger RIG across most businesses. Latin America maintained momentum with strong performances in our largest markets of Brazil and Mexico contributing strongly to RIG, as pricing moderated.
• Market share continued to improve in Petcare and remained broadly stable across Coffee and Food & Snacks, with some share loss in Nutrition.

Q3-26 key growth drivers by product category

• Coffee (19% of Zone sales): OG was low single digit, driven by pricing. In the US, RIG is improving, driven by progressive recovery from the initial impact of price increases taken earlier in the year in Starbucks and Nescafé, as well as improvement in Coffee mate. Outside the US, OG was driven by mid single-digit RIG, with continued strength in markets such as Mexico and Brazil.
• Petcare (30% of Zone sales): OG strengthened to mid single digit, led by RIG with positive price contribution. Growth accelerated in the US, with mid single-digit RIG as category fundamentals and execution continued to strengthen and sell-in matched strong sell-out. Performance was further fueled by strong growth in Latin America.
• Nutrition (21% of Zone sales): OG was low single digit, driven by pricing. Medical nutrition was the standout performer, with OG accelerating for the sixth consecutive quarter. This was partially offset by adult nutrition, with Pure Encapsulations remaining strong but weaker performance in the quarter in some other brands. Performance in Gerber shows signs of stabilization.
• Food & Snacks (30% of Zone sales): OG was mid single digit, accelerating from the previous quarter and led by RIG across all segments. Confectionery delivered strong RIG, with good underlying momentum and market share gains, supported by some earlier seasonal orders. Growth in food benefited from improved performance in US frozen food brands Stouffer’s, DiGiorno and Hot Pockets with positive market share trends despite the challenging category environment.

 

Zone Asia, Oceania and Africa (AOA)

9M-26 operating performance

• OG was 5.0%, with RIG of 3.5% and pricing of 1.5%.
• Reported sales were CHF 15.7 billion, including a negative impact of 5.4% from foreign exchange movements.

Q3-26 sales performance
In Zone AOA, we maintained our strong growth momentum even against a tougher prior year comparison base. OG was strong and broad based across most country-category combinations with India, MENA, Japan and Malaysia & Singapore all delivering double-digit growth. Growth continued to be RIG-led, reflecting positive business momentum across the Zone.

• For Zone AOA, OG was 6.4%, in line with the strong performance delivered in Q2. RIG improved further to 5.0%, the Zone’s highest quarterly RIG since Q1-21, while pricing moderated to 1.3%.
• In AOA excluding Greater China, OG was 6.9%, with 5.4% RIG and 1.6% pricing. Growth was positive across most markets. India achieved 20% OG on a base of double-digit growth in Q3-25, gaining further market share.
• Greater China delivered 4.2% OG, comprising 3.7% RIG and 0.5% pricing. Growth reflects a low comparison base from the trade inventory reduction in 2025 along with some continued improvement in underlying performance, but market conditions remain challenging.
• The Zone gained market share overall, excluding Nutrition. Market share gains were achieved in Petcare and Food & Snacks, with Coffee improving further and Nutrition still impacted by the recall.

Q3-26 key growth drives by product category

• Coffee (25% of Zone sales): OG remained high single digit, led by RIG. Growth was driven by Nescafé across all formats, including double-digit growth in OOH. Continued momentum in cold coffee was also notable, driven by ready-to-drink expansion, liquid concentrates acceleration and soluble iced coffee offerings.
• Petcare (4% of Zone sales): OG accelerated to double digit, driven by strong RIG. Growth accelerated in emerging markets and remained steady in developed markets. Pro Plan, ONE and Felix continued to deliver strong growth and we strengthened our leadership in wet cat food in key geographies, supported by continued investment in the category.
• Nutrition (32% of Zone sales): OG was low single digit as performance continued to stabilize. Infant nutrition returned to positive growth showing consistent recovery across our markets and driven by strong contribution from Lactogen. Successful innovations helping to drive growth include Ascenda catch-up growth formula and the rollout of our unique 10-HMO formulations within illuma.
• Food & Snacks (39% of Zone sales): Another quarter of very strong performance, with OG approaching double digit, driven by RIG. Growth was broad-based across all major businesses and primarily driven by our billionaire brands. Maggi contributed strongly through savory cooking solutions and noodles. Milo maintained strong momentum with product extensions to target new age groups and new consumption occasions. KitKat was supported by new launches and Formula 1 and ‘Break Better’ activations.

 

Zone Europe

9M-26 operating performance

• OG was 2.2%, with RIG of 0.7% and pricing of 1.5%.
• Reported sales were CHF 13.7 billion, with a negative impact of 2.8% from foreign exchange movements.

Q3-26 sales performance
Performance in Zone Europe was solid, with positive market share trends underpinned by disciplined execution. RIG recovered from the weaker Q2, despite the continued competitive environment, driven by continued strength in Petcare and an improvement in Food & Snacks. As expected, pricing moderated as we lapped increases taken last year and in the context of a strong customer and competitor focus on providing value for consumers.

• OG was 1.2%, with RIG of 1.0% and pricing of 0.2%.
• By market, trends were mixed. RIG was driven by the Nordics, France and Iberia; Germany continues to be challenging but with sequential improvement.
• Market share strengthened further in Petcare, and trends continued to improve in Coffee and Food & Snacks. In Nutrition, market share remains impacted by the infant formula recall.

Q3-26 key growth drivers by product category

• Coffee (27% of Zone sales): OG was low single digit, driven by moderating pricing in a competitive environment. The slowdown in OG through the first three quarters of 2026 primarily reflects a progressively higher comparison base. In Q3, growth was supported by strong contributions from Nescafé ready-to-drink and Starbucks by Nespresso portion coffee.
• Petcare (30% of Zone sales): Petcare again delivered mid single-digit OG, driven by RIG. Wet cat food continues to be the main growth engine, along with double-digit OG in therapeutics and supplements. Growth was broad-based across markets and brands, led by double-digit OG in Felix and Pro Plan, and we continued to perform very strongly in e-commerce.
• Nutrition (14% of Zone sales): OG declined low single digit due to the infant formula recall across Europe. Outside infant nutrition, growth was led by consistent performance in medical nutrition, with continued strong sales growth in Compleat following its launch in 2025.
• Food & Snacks (29% of Zone sales): OG decline improved to low single digit. The environment remains difficult across several markets, and the hot weather was an additional headwind for confectionery demand. Despite this, growth improved in Maggi and Nestlé Confectionery and remained positive in KitKat.

 

Nespresso

9M-26 operating performance

• OG was 3.7%, with RIG of 1.5% and pricing of 2.2%.
• Reported sales were CHF 4.7 billion, impacted by a negative effect of 3.0% from foreign exchange movements.

Q3-26 sales performance
Nespresso delivered solid OG in the quarter against a strong prior year comparison base. Brand campaigns, seasonal editions and accessories are all resonating well with consumers, supporting new member recruitment. Sales growth in 2026 has been impacted by moderating pricing and some consumption softness. Despite this, capsule volume growth trends are positive, helped by an improvement in Europe.

• OG was 2.5%, with RIG of 1.1%; pricing was 1.4%, easing compared to the previous quarter as we cycle prior year increases.
• By geography, performance was led by North America with mid single-digit growth in the US and high single-digit growth in Canada. Growth was flat in Europe and in AOA.
• By system, Vertuo remains the primary growth driver, delivering high single-digit OG and RIG. Growth was supported by the Vertuo World campaign with Dua Lipa and the successful launch of the new Vertuo Up machine, helping to drive consumer adoption globally.
• By channel, OOH grew mid single digit across geographies, driven by higher customer consumption, growth in HORECA, and innovation supporting an acceleration in machine placements.
• Market share gains continued in North America and AOA, while Europe remains pressured across key markets due to ongoing competitive intensity.
• Seasonal editions and accessories continue to resonate strongly with consumers, supporting new member recruitment and reinforcing Nespresso‘s premium lifestyle proposition.
• Nespresso was proud to renew its B Corp Certification under B Lab’s new standards during the quarter.

 

Nestlé Waters & Premium Beverages

9M-26 operating performance

• Organic growth was 7.5%, with RIG of 3.5% and pricing of 4.0%.
• Reported sales were CHF 2.8 billion, with a negative impact of 4.6% from foreign exchange movements.

Q3-26 sales performance
Nestlé Waters & Premium Beverages continued to accelerate, delivering double-digit OG and gaining market share globally. Growth was driven by strong category fundamentals, and robust demand for our international brands and premium beverages innovations, supported by favorable weather in Europe.

• Organic growth was 12.3%, driven by RIG of 7.3% and pricing of 5.0%.
• Growth was broad-based across markets, led by North America along with an acceleration in Europe and AOA. Growth in Europe benefited from favorable weather.
• International brands continued to perform strongly delivering double-digit growth. The platforms Sanpellegrino and Maison Perrier strongly contributed to this growth reflecting the international expansion of Maison Perrier and the successful rollout of premium beverages innovations. These included Sanpellegrino CIAO! and ZERO, Maison Perrier French Kiss.
• By channel, retail and OOH delivered double-digit growth benefiting from strong category momentum during the peak season and favorable weather conditions in Europe.
• Market share gains globally with a strong contribution in key international brands.

 

Performance by product category

Q3-2026 sales performance

	Total Group	Coffee	Petcare	Nutrition	Food & Snacks	Waters & Premium Beverages
Sales Q3-2026 (CHF m)	22 756	6 155	4 659	4 440	6 469	1 033
Sales Q3-2025 (CHF m)	21 641	5 976	4 354	4 350	6 029	932
Real internal growth (RIG)	2.8%	1.3%	4.3%	– 1.1%	5.4%	7.3%
Pricing	1.1%	2.0%	1.0%	1.4%	– 0.4%	5.0%
Organic growth	4.0%	3.4%	5.3%	0.3%	5.0%	12.3%

Coffee delivered 3.4% OG in Q3-26, driven by pricing of 2.0%, which continues to ease, along with RIG of 1.3%. Growth was broad-based across geographies and led by the performance of Nescafé, and Starbucks. Performance in creamers improved in the quarter, driven by better RIG in Coffee mate, with strong contributions from Starbucks and Natural Bliss.

Petcare OG was 5.3% in Q3-26, with RIG of 4.3%. Performance was strong across all geographies. Growth was driven by continued strong performance in cat, with sell-in matching strong sell-out. Dog remained soft, partly reflecting the impact of warmer weather on consumption. Therapeutics growth accelerated, supported by focused investments. Our largest brands including Pro Plan and ONE continued to deliver strong sales growth.

Nutrition OG was 0.3% in Q3-26, with RIG of -1.1% and pricing of 1.4%. RIG reflected weaker performance in kids & all family and infant nutrition. The impact of the infant formula recall continued to ease, with performance in the category improving through the quarter. Medical nutrition delivered another strong quarter, while adult nutrition slowed. Pure Encapsulations continues to perform strongly, delivering consistent double-digit sales growth.

Food & Snacks recorded OG of 5.0%, driven by RIG. Growth was broad-based across all segments, led by confectionery and cooking solutions and strong momentum in both AMS and AOA supported by seasonal order phasing. Growth continued to be driven by our global-leading billionaire brands Maggi, Milo and KitKat.

 

Annex

Nine-month performance

	Total Group	Zone Americas	Zone Asia, Oceania and Africa	Zone Europe	Nespresso	Nestlé Waters & Premium Beverages	Other businesses
Sales 9M-2026 (CHF m)	65 865	28 735	15 706	13 724	4 740	2 814	146
Sales 9M-2025 (CHF m)	65 869	28 693	15 782	13 716	4 706	2 753	219
Real internal growth (RIG)	1.9%	1.5%	3.5%	0.7%	1.5%	3.5%	2.3%
Pricing	1.8%	1.8%	1.5%	1.5%	2.2%	4.0%	– 0.4%
Organic growth	3.7%	3.3%	5.0%	2.2%	3.7%	7.5%	2.0%
Net M&A	– 0.1%	0.0%	– 0.2%	0.8%	0.1%	– 0.7%	– 31.3%
Foreign exchange	– 3.7%	– 3.1%	– 5.4%	– 2.8%	-3.0%	– 4.6%	– 4.1%
Reported sales growth	0.0%	0.1%	– 0.6%	0.2%	0.7%	2.2%	– 33.4%

 

	Total Group	Coffee	Petcare	Nutrition	Food & Snacks	Water & Premium Beverages
Sales 9M-2026 (CHF m)	65 865	18 281	13 591	12 779	18 400	2 814
Sales 9M-2025 (CHF m)	65 869	17 992	13 583	13 432	18 106	2 756
Real internal growth (RIG)	1.9%	2.4%	2.6%	– 1.2%	3.1%	3.5%
Pricing	1.8%	3.8%	0.9%	0.5%	1.0%	4.0%
Organic growth	3.7%	6.1%	3.5%	– 0.7%	4.2%	7.5%

 

Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth

sBLA for VYVGART Hytrulo in IMNM on track for submission by year-end; pursuing additional registrational study in DM

Phase 3 MMN data for empasiprubart expected in December 2026

FB102 advancing to Phase 3 in celiac disease as potential new growth pillar in argenx’s next wave of immunology innovation

Management to host conference call today at 2:30 PM CET (8:30 AM ET)

October 22, 2026 7:00 AM CET

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced its third quarter 2026 results and provided a business update.

“The story of argenx is one of continued innovation, growth and impact,” said Karen Massey, Chief Executive Officer. “VYVGART is the foundation of our business and continues to deliver strong performance across gMG and CIDP, with significant opportunity still ahead as we reach more patients, expand into new indications, and advance the next wave of FcRn medicines. The positive results from our Phase 3 ALKIVIA study further reinforce the potential of VYVGART beyond neurology, and underscore how much more it can deliver for patients. The upcoming Phase 3 readout for empasiprubart in MMN, the advancement of FB102, and progress across our emerging immunology pipeline are bringing the next chapter of argenx into focus as we build a global immunology innovator positioned for durable growth and value creation well beyond Vision 2030.”

Vision 2030
argenx remains on track to achieve its ‘Vision 2030’ anchored in the ambition to treat 50,000 patients globally with its medicines, secure 10 labeled indications, and progress five pipeline candidates into registrational development by 2030.

Realizing the full potential of VYVGART and advancing FcRn leadership
VYVGART^® (IV: efgartigimod alfa-fcab; SC: efgartigimod alfa and hyaluronidase-qvfc) is the first-and-only approved treatment for all adult patients living with generalized myasthenia gravis (gMG). It is also approved for chronic inflammatory demyelinating polyneuropathy (CIDP) globally, and primary immune thrombocytopenia (ITP) in Japan. Building on VYVGART’s leadership in MG and CIDP, argenx is progressing multiple label and indication expansions, exploring VYVGART’s potential in additional autoimmune diseases through proof-of-concept studies, and advancing next-generation FcRn molecules and delivery modalities.

• Generated $1.7 billion in global product net sales in the third quarter of 2026, representing 54% year-over-year growth and 13% quarter-over-quarter growth
• Submitted a Supplemental Biologics License Application (sBLA) for VYVGART in ocular myasthenia gravis (oMG) to the U.S. Food and Drug Administration (FDA)
• sBLA for VYVGART and VYVGART Hytrulo in pediatric gMG accepted for priority review by the FDA with a PDUFA target action date in February 2027
• VYVGART Hytrulo autoinjector expected to launch in second half of 2027 for all approved indications
• Reported positive Phase 3 ALKIVIA results with consistent and clinically meaningful treatment effects observed across immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM); sBLA for VYVGART Hytrulo in IMNM on track for submission by year-end 2026, supported by Breakthrough Therapy Designation, with plans to conduct an additional registrational study in DM
• Topline results from Phase 3 ADVANCE-NEXT study in primary ITP expected in first half of 2027
• Phase 3 VitaliThy studies in Graves’ disease ongoing
• Advancing the future FcRn portfolio, including Phase 3-ready ARGX-213, designed for monthly dosing, and ARGX-124 currently in Phase 1 development

Advancing empasiprubart, argenx’s second pipeline-in-a-product opportunity
Empasiprubart (anti-C2) is argenx’s second pipeline-in-a-product opportunity and is being evaluated in Phase 3 studies in multifocal motor neuropathy (MMN) and CIDP, with additional Phase 2 studies exploring its potential in other indications and in combination with VYVGART in gMG.

• Topline results from the Phase 3 EMPASSION study (MMN) expected in December 2026
• Topline results from Phase 3 EMVIGORATE and EMNERGIZE studies in CIDP anticipated in the second half of 2027
• Phase 2 ADAPT-Forward platform study in gMG ongoing, evaluating empasiprubart as an add-on to efgartigimod and as monotherapy to support combination development pathway

Delivering next wave of immunology innovation
Beyond the FcRn portfolio and empasiprubart, argenx is advancing a differentiated immunology pipeline that includes FB102 (CD122), adimanebart (MuSK), ARGX-121 (IgA), ARGX-109 (IL-6), TSP-101 (Fn14), ARGX-118 (Galectin-10) and ARGX-125 (undisclosed target), together with additional candidates emerging from the Immunology Innovation Program. These programs support argenx’s ambition to build multiple pillars of sustainable growth beyond Vision 2030.

• Advancing FB102 to Phase 3 in celiac disease based on positive Phase 2 results, with ongoing programs in alopecia areata and vitiligo and potential across other autoimmune diseases
• Phase 3 study of adimanebart in congenital myasthenic syndromes (CMS) expected to begin in 2026; Phase 2 in spinal muscular atrophy (SMA) ongoing
• Phase 2 study of ARGX-121 in IgA nephropathy (IgAN) ongoing
• Advancing Phase 1 development of TSP-101, ARGX-118 and ARGX-125

THIRD QUARTER 2026 FINANCIAL RESULTS
argenx SE
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS

		Three Months Ended						Nine Months Ended
		September 30,						September 30,
(in millions of $ except for per share data)		2026			2025			2026				2025
Product net sales		$	1,721		$	1,127		$	4,534		$	2,866
Other operating income			30			24			71			60
Total operating income		$	1,751		$	1,151		$	4,605		$	2,926
Cost of sales		$	(165)		$	(109)		$	(431)		$	(301)
Research and development expenses*			(503)			(359)			(1,432)			(1,001)
Selling, general and administrative expenses			(598)			(336)			(1,370)			(937)
Total operating expenses		$	(1,266)		$	(805)		$	(3,233)		$	(2,240)
Operating profit		$	486		$	346		$	1,372		$	686
Financial income		$	45		$	43		$	137		$	118
Financial expense			(1)			(1)			(3)			(3)
Exchange gains/(losses)			8			(2)			(11)			74
Profit for the period before taxes		$	538		$	386		$	1,495		$	875
Income tax expense		$	(32)		$	(42)		$	(151)		$	(116)
Profit for the period		$	506		$	344		$	1,344		$	759
Profit for the period attributable to:
Owners of the parent		$	506		$	344		$	1,344		$	759
Weighted average number of shares used for basic profit per share			62,735,385			61,371,508			62,370,746			61,147,873
Basic profit per share (in $)			8.07			5.61			21.54			12.41
Weighted average number of shares used for diluted profit per share			64,886,406			66,441,326			64,578,235			65,944,952
Diluted profit per share (in $)			7.80			5.18			20.81			11.51

*Comparative figures have been aligned with the presentation adopted in the current period, reflecting the combination of research and development expenses and loss from investment in a joint venture.

DETAILS OF THE FINANCIAL RESULTS

Total operating income for the three and nine months ended September 30, 2026 was $1.8 billion and $4.6 billion, respectively, compared to $1.2 billion and $2.9 billion, respectively, for the same periods in 2025, and mainly consisted of:

• Product net sales of VYVGART for the three and nine months ended September 30, 2026, were $1.7 billion and $4.5 billion, respectively, compared to $1.1 billion and $2.9 billion, respectively, for the same periods in 2025.
• Other operating income for the three and nine months ended September 30, 2026 was $30 million and $71 million, respectively, compared to $24 million and $60 million, respectively, for the same periods in 2025. The other operating income in these periods primarily related to research and development tax incentives and payroll tax rebates.

Total operating expenses for the three and nine months ended September 30, 2026 were $1.3 billion and $3.2 billion, respectively, compared to $0.8 billion and $2.2 billion, respectively, for the same periods in 2025, and mainly consisted of:

• Cost of sales for the three and nine months ended September 30, 2026 was $165 million and $431 million, respectively, compared to $109 million and $301 million, respectively, for the same periods in 2025. The cost of sales was related to the sale of VYVGART.
• Research and development expenses for the three and nine months ended September 30, 2026 were $0.5 billion and $1.4 billion, respectively, compared to $0.4 billion and $1.0 billion, respectively, for the same periods in 2025. The research and development expenses mainly related to advancing efgartigimod, empasiprubart, adimanebart and FB102 across multiple registrational studies, plus early-stage pipeline and preclinical programs.
• Selling, general and administrative expenses for the three and nine months ended September 30, 2026 were $0.6 billion and $1.4 billion, respectively, compared to $0.3 billion and $0.9 billion, respectively, for the same periods in 2025. The selling, general and administrative expenses mainly related to professional and marketing fees linked to the global commercialization of the VYVGART franchise, and personnel expenses. Selling, general and administrative expenses for the three- and nine-month periods ended September 30, 2026 included approximately $150 million of acquisition-related expenses associated with the Company’s acquisition of Forte Biosciences Inc.

Financial income for the three and nine months ended September 30, 2026 was $45 million and $137 million, respectively, compared to $43 million and $118 million, respectively, for the same periods in 2025.

Exchange gains/losses for the three and nine months ended September 30, 2026 were an $8 million gain and an $11 million loss, respectively, compared to a $2 million loss and a $74 million gain, respectively, for the same periods in 2025.

Income tax for the three- and nine-month periods ended September 30, 2026 and 2025 is detailed below:

		Three Months Ended						Nine Months Ended
		September 30,						September 30,
(in millions of $)		2026			2025			2026			2025
Current tax expense		$	(129)		$	(52)		$	(359)		$	(122)
Deferred tax benefit			97			10			208			6
Income tax expense		$	(32)		$	(42)		$	(151)		$	(116)

Profit for the three- and nine-month periods ended September 30, 2026 was $0.5 billion and $1.3 billion, respectively, compared to $0.3 billion and $0.8 billion, respectively, for the same periods in 2025. The basic profit per share was $8.07 for the three months ended September 30, 2026, compared to $5.61 for the same period in 2025. The basic profit per share was $21.54 for the nine months ended September 30, 2026, compared to $12.41 for the same period in 2025.

Cash, cash equivalents and current financial assets¹ consisted of $2.6 billion in cash and cash equivalents and $1.1 billion in current financial assets which totaled $3.7 billion as of September 30, 2026 after paying approximately $2.1 billion for the acquisition of Forte Biosciences Inc., net of acquired cash, compared to $3.5 billion in cash and cash equivalents and $0.9 billion in current financial assets which totaled $4.4 billion as of December 31, 2025.

FULL YEAR EXPECTATIONS
Combined R&D and SG&A expenses are now expected to be approximately $4 billion for 2026, including the Forte transaction-related costs.

EXPECTED FINANCIAL CALENDAR

• February 25, 2027: Full-year 2026 Financial Results and Fourth Quarter 2026 Business Update
• April 29, 2027: First Quarter 2027 Financial Results and Business Update
• July 22, 2027: Half Year and Second Quarter 2027 Financial Results and Business Update
• October 21, 2027: Third Quarter 2027 Financial Results and Business Update

CONFERENCE CALL DETAILS
The third quarter 2026 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 PM CET/8:30 AM ET. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors.

Participants can access the conference call by dialing 800-590-8290 (United States and Canada) or 240-690-8800 (International). Country specific dial-in numbers are listed below:

Belgium                32 2290 4635
France                        33 172 001717
Netherlands                31 20 795 2683
United Kingdom                44 203 393 1560
Japan                        81 3 4520 9761
Switzerland                41 43 210 51 68

Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.

A replay of the webcast will be available on the argenx website.

About VYVGART
VYVGART® (efgartigimod alfa fcab) is a first-in-class human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. VYVGART Hytrulo® is a subcutaneous combination of efgartigimod alfa (VYVGART) and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology to facilitate subcutaneous injection delivery of biologics. VYVGART is approved for generalized myasthenia gravis (gMG) and immune thrombocytopenia (Japan only). VYVGART Hytrulo is approved for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo may be marketed under different proprietary names in other regions.

About argenx
argenx is the immunology innovation company, focused on turning immunology breakthroughs into medicines for patients. The company seeks novel biology wherever it emerges, co-creating with academic researchers through its Immunology Innovation Program (IIP) and investing in promising science, to develop treatments for people living with underserved diseases. By advancing molecules with the potential to reach multiple diseases and patient populations, argenx is building a world-class portfolio. This approach produced the first approved antibody fragment targeting the neonatal Fc receptor (FcRn) and today powers a growing pipeline of early and late-stage programs across several therapeutic areas. For more information, visit  www.argenx.com  and follow us on LinkedIn, Instagram, Facebook, and YouTube.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).

Contacts
Media:
Ben Petok
bpetok@argenx.com

Investors:
Alexandra Roy
aroy@argenx.com

Forward Looking Statements
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements generally can be identified by the use of forward-looking words, such as “ahead”, “aim”, “ambition,” “anticipate”, “aspire”, “believe”, “can”, “continue”, “could”, “designed for”, “estimate”, “expect”, “entail”, “forecast”, “future”, “goals”, “hope”, “intend”, “is designed to”, “likely”, “may”, “might”, “objective”, “plan”, “possible”, “positioned”, “potential”, “pursue”, “project”, “predict”, “seek”, “should”, “strategy”, “target”, “upcoming”, “will” and other words and terms of similar meaning and expression, including in connection with any discussion of future operating or financial performance. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, uncertainties associated with the development of novel drug therapies; the initiation, timing, progress, development and results of preclinical and clinical trials of argenx’s product candidates, including new indications, alternative dosing regimens, treatment modalities, and methods of administration, including statements regarding when results or interim analysis of the clinical trials will be available or made public; the risk that early stage clinical trials may not be predictive of results in later stage or large scale clinical trials; the expansion of argenx’s business, including the further development of argenx’s sales and marketing abilities and its Immunology Innovation Program, and the value of its pipeline; the potential attributes, benefits, and side effects of argenx’s products and product candidates, including new indications, alternative dosing regimens and treatment modalities, and their competitive position with respect to other alternative treatments; argenx’s ability to advance product candidates into, and successfully complete, clinical trials; argenx’s estimates of the number of patients who suffer from the diseases it is targeting and the number of patients that will enroll in its clinical trials; the demand and commercialization of argenx’s products and product candidates, including new indications, alternative dosing regimens, treatment modalities, and methods of administration, if approved; the anticipated timing or likelihood of market or regulatory decisions relating to or of argenx’s products, including new indications, alternative dosing regimens, treatment modalities, and methods of administration; the anticipated pricing and reimbursement of argenx’s products and product candidates, if approved; argenx’s plans to have various programs to help patients afford its products, including patient assistance and co-pay coupon programs for eligible patients; argenx’s ability to establish sales, marketing and distribution capabilities for any of its products and product candidates that achieve regulatory approval; argenx’s regulatory strategy and its ability to establish and maintain manufacturing arrangements for its products and product candidates; the scope and duration of protection, including any exclusivity period, argenx is able to establish and maintain for intellectual property rights covering its products and product candidates, platform and technology, including its intention to seek patent term extensions where available; argenx’s estimates regarding expenses, future revenues, cash flow, capital requirements and its needs for additional financing; argenx’s expectation that it will benefit from the Belgian innovation income deduction; argenx’s financial performance, including potential volatility in the price of its ordinary shares and American Depositary Shares; the acquisition of Forte Biosciences Inc., including argenx’s ability to integrate the acquired business and realize its anticipated benefits; the competition argenx faces in its drug discovery, development, and commercialization efforts; the rate and degree of market acceptance of argenx’s products and product candidates, if approved, by its patients as safe, effective and cost-effective; the potential benefits of argenx’s current collaborations, including the possibility to access partner technology platforms or capabilities; argenx’s plans and ability to enter into or maintain current collaborations for additional programs or product candidates; argenx’s plans and ability to enter into or maintain current new distribution partnerships; argenx’s long-term growth strategy to develop and market additional products and product candidates, including but not limited to, efgartigimod for new indications, empasiprubart, adimanebart, and FB102; the impact of government laws and regulations, including tariffs, export controls, sanctions and other regulations on argenx’s business; argenx’s expectations with respect to the timing and amount of any dividends (if any); argenx’s plans regarding its supply chain, including its reliance on third parties, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; regional instability and conflicts; and argenx’s business strategies, including Vision 2030, plans, projects, goals and targets and the timing, outcomes and benefits thereof. A further list and description of these and other risks, uncertainties, and factors that could cause actual results to differ materially from those referred to in the forward-looking statements can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these risks and uncertainties, the reader is advised not to place undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this press release. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

Alternative Performance Measures Statement
In this document, argenx’s financial results are provided in accordance with IFRS® Accounting Standards (IFRS) and using a non-IFRS financial measure, cash, cash equivalents and current financial assets.

This value should not be viewed as a substitute for the company’s IFRS financial information and is provided as a complement to financial information provided in accordance with IFRS and should be read in conjunction with the most directly comparable IFRS financial information as set out below. Management believes this non-IFRS financial measure is useful for securities analysts, investors and other interested parties to gain a more complete understanding of the company’s available financial liquidities given that the company’s current financial assets are held in term accounts with an initial maturity of more than three months but less than twelve that may be used to meet its financial obligations. Such non-IFRS financial information, as calculated herein, may not be comparable to similarly named measures used by other companies and should not be considered comparable to IFRS financial measures. Non-IFRS financial measures have limitations as an analytical tool and should not be considered in isolation from, or as a substitute for, an analysis of the company’s financial results as reported under IFRS.

A reconciliation of the IFRS financial information to non-IFRS financial information is included below:

Cash, cash equivalents and current financial assets totaled $3.7 billion as of September 30, 2026, compared to $4.4 billion as of December 31, 2025. The balance as of the period ended September 30, 2026 consisted of $2.6 billion in cash and cash equivalents and $1.1 billion in current financial assets and the balance as of the period ended December 31, 2025 consisted of $3.5 billion in cash and cash equivalents and $0.9 billion in current financial assets.

---

¹ A non-IFRS Alternative Performance Measure (APM). Refer to the “Alternative Performance Measures Statement” below for a reconciliation to the IFRS financial information.

The Board of Telia Lietuva, AB (hereinafter “Telia Lietuva” or “the Company”) approved unaudited Telia Lietuva, AB Interim Financial Statements, prepared according to International Financial Reporting Standards as adopted by the European Union, for 9 months’ period ended 30 September 2026.

Third quarter of 2026 (compared with the same period a year ago):

• Revenue went up by 9.7% and amounted to EUR 137.4 million (EUR 125.3 million)
• Adjusted EBITDA up by 9.5% to EUR 55.8 million (EUR 51 million)
• EBITDA increased by 9.2% and amounted to EUR 55.7 million (EUR 51 million)
• Profit for the period grew by 19.9% to EUR 27.5 million (EUR 22.9 million)
• Capital investments went up by 24.5% and amounted to EUR 19 million (EUR 15.2 million)
• Free cash flow went down by 47.8% and amounted to EUR 17.8 million (EUR 34.2 million)

9 months of 2026 (compared with the same period a year ago):

• Revenue was up by 8% and amounted to EUR 396.5 million (EUR 367 million)
• Adjusted EBITDA up by 9.9% to EUR 162.7 million (EUR 148 million)
• EBITDA increased by 9.4% and amounted to EUR 161.1 million (EUR 147.3 million)
• Profit for the period went up by 16.5% to EUR 78.8 million (EUR 67.7 million)
• Capital investments increased by 44.8% and amounted to EUR 56.4 million (EUR 39 million)
• Free cash flow went down by 10.1% and amounted to EUR 81.9 million (EUR 91.1 million)

Comment by Giedrė Kaminskaitė-Salters, CEO of Telia Lietuva:
During the third quarter of 2026 we continue to grow in all our core areas of activities dominated by IT and mobile services development. The total revenue for the nine months, compared with the same period a year ago, increased by 8 per cent whereof service revenue grew by 6.6 per cent, while equipment sales went up by 15 per cent. Over the year, adjusted EBITDA for January-September of 2026 increased by 9.9 per cent and reached a 41 per cent margin (40.3 per cent in 2025), and net profit for the period went up by 16.5 per cent. Higher capital expenditure during the third quarter of 2026 resulted in free cash flow contracting by 10.1 per cent for the nine months period compared with the same period a year ago.

In September 2026, an important milestone in the construction of our new data center near Vilnius was reached. The first phase – erection of the main building – was completed. The EUR 26 million value project is scheduled for completion in the second quarter of 2027, after which the installation and testing of the data center’s engineering and IT infrastructure systems will begin. These works are planned to be completed by the end of 2028, when the two initial data center modules with more than 400 racks will be ready to welcome the first customers. The new data center will allow the Company to double the capacity of the data centers it currently operates in Lithuania.

To maintain technological leadership, we plan to invest EUR 7.1 million in the expansion of our mobile network. With this project we will construct 50 new base stations, modernize 300 existing sites and upgrade around 130 additional sites with new radio equipment. We are starting to deploy the 1,500 MHz spectrum acquired in the recent auction, increasing 5G network capacity to support continued growth in mobile data traffic. Telia Lietuva currently operates the largest 5G network in Lithuania, comprising 1,830 base stations, with 5G coverage reaching 99.7% of the country’s territory.

The Company has been awarded the contract to provide critical IT and telecommunications infrastructure for Lithuania’s Presidency of the Council of the European Union in 2027. During the six-month Presidency, Telia Lietuva will deliver secure and resilient connectivity solutions, including internet services, wired and wireless networks, cybersecurity, and other technological solutions.

On consumers side, Telia Lietuva strengthened its content leadership with Disney+ integration into Telia Play. Following the successful integration of Netflix and HBO Max, Telia Play continued to expand its premium entertainment offering with the addition of Disney+, one of the world’s leading streaming platforms.

Telia Lietuva has once again secured first place in the Dive customer service survey in Lithuania. We have achieved the top rating six times over the past seven years.

As part of our desire to play a leading role in Lithuania’s defense, Telia Lietuva has announced that it will pay up to EUR 2,300 (before income tax) per month for up to nine months to employees who voluntarily choose military service. Their jobs and key additional benefits will be preserved, and a smooth return to work after service will be ensured. In doing so, the Company joins the ‘Visuotinė gynyba’ (Total Defense) association’s initiative, which encourages businesses to create better conditions for people wishing to contribute to the country’s defense effort.

As the next step in becoming a simpler, faster and more efficient company, Telia Lietuva plans to reduce its workforce during December 2026 with around 85 employees across all units to receive notices of proposed redundancy. This change is part of Telia Company’s Group restructuring operations across the Nordic and Baltic countries. The Group is simplifying its organizational structure by giving country teams more responsibility, reducing costs and targeting higher profitability. It is planned to complete the organizational restructuring by the end of 2026.

ENCL.:
– Telia Lietuva, AB Interim Report for January-September of 2026.
– Presentation of Telia Lietuva, AB results for 9 months of 2026.

Darius Džiaugys,
Head of Investor Relations,
tel. +370 5 236 7878,
e-mail: darius.dziaugys@telia.lt

Attachments

• Telia Lietuva_2026_9 months_Interim_Report
• Telia_Lietuva_2026_9_months_results_presentation

• Attractive biodistribution supports selection of MP0730 as Radio-DARPin therapy candidate 
• CD70 is a clinically validated target expressed in kidney cancer and other indications
• First-in-human program expected to start in H2 2027

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the selection of MP0730 as its lead Radio-DARPin candidate targeting the tumor-associated antigen CD70. MP0730 is the third program in the Company’s pipeline of targeted alpha radiotherapeutics, and a first-in-human program is expected to start mid-2027.

Molecular Partners presented preclinical data on MP0730 at the Discovery on Target – Radioligand Therapies conference on October 1, 2026, in Boston, MA (presentation title: DARPins as Ligands for Targeted Alpha Therapy: First-in-Human Experience with MP0712 and Opportunities for Next Radio-DARPin Candidates). The data outline an attractive biodistribution profile of the CD70-targeting Radio-DARPin lead candidate in tumor-bearing mice, with strong and sustained tumor uptake relative to healthy tissues, including kidney, liver and blood.

“The selection of MP0730 as our third Radio-DARPin Therapeutic marks another important milestone in our ambition to deliver transformative therapies for patients with high unmet medical needs. CD70’s clean expression profile paired with MP0730’s best-in-class properties provide a compelling foundation for achieving a favorable therapeutic index, addressing on-target, off-tumor accumulation observed with certain radiopharmaceutical approaches against other antigens expressed in kidney cancer,” said Daniel Steiner, Ph.D., SVP Targeted Radiotherapeutics of Molecular Partners.

CD70 is a clinically validated target, demonstrated through CAR-T cell therapies, and is overexpressed in clear cell renal cell carcinoma (ccRCC), a type of kidney cancer, and in other cancer indications. CD70 expression is maintained in metastases and limited in healthy tissues, making it an ideal candidate for targeted alpha radiotherapy.

ccRCC has a robust DNA repair mechanism and is inherently resistant to conventional cytotoxic therapies. Targeted alpha therapy induces difficult-to-repair double-strand breaks in tumor cells, independently from genetic mutations, due to its high linear energy transfer, thereby offering a new avenue for patients with hard-to-treat cancers such as ccRCC.

About Radio-DARPins
Molecular Partners develops targeted alpha therapeutics leveraging its Radio-DARPins as isotope-agnostic vectors to unlock a broad range of cancer targets and indications. The Company tailors its radiotherapeutic candidates by matching vector and isotope properties with disease and target biology to address unmet medical needs. Designed for precise delivery of potent radioactive payloads to tumor lesions, Molecular Partners’ Radio-DARPins address historic limitations of radioligand therapy, such as kidney accumulation and suboptimal tumor uptake, through optimized half-life extension and surface engineering approaches. In addition, the Company’s Radio-DARPins support swapping of chelator and isotope while maintaining comparable biodistribution of candidates, thereby offering potential competitive advantages over other vectors. DARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of medicines – with key properties such as exquisite specificity, high affinity, small size – which have been clinically-validated across several disease areas, tested in >2500 patients globally, and developed through to the registrational stage.

About Molecular Partners AG 
Molecular Partners AG (SIX, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of medicines known as DARPin therapeutics for cancer patients underserved by existing treatment modalities. Molecular Partners focuses on the development of targeted radiotherapeutics, leveraging the unique properties of DARPin miniproteins as isotope-agnostic vectors. The Company’s lead medicine MP0712, targeting DLL3 and armed with ²¹²Pb, advances in a US multicenter Phase 1/2a study for patients with small cell lung cancer and other neuroendocrine cancers. Molecular Partners has established partnerships with industry leaders and academic centers covering the full value chain of radiotherapeutics. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn.

For further details, please contact:
Seth Lewis, EVP Corporate Finance
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Corporate Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, “anticipate”, “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include, but are not limited to, those set forth under the heading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2025 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future.

Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

In the third quarter of 2026, Harju Elekter Group generated sales revenue of 41 million euros, approximately 5% lower than in the corresponding period last year. While sales volumes have not yet reached the desired level, the quarter was the strongest of the year in terms of profitability. Operating profit amounted to 2.3 million euros, and the operating margin increased to 5.7%, exceeding the Group’s minimum target level of 5%. 

Profitability continued to be affected by projects that had previously been postponed, the execution of which depends, among other factors, on the delivery of certain customer-specific components. As a result, the realization of part of the planned production volumes was once again delayed. At the same time, workload remained below expectations in several units, particularly at the Lithuanian factory, due to a shortage of orders. In Finland, the key challenge has been growing the project business at the desired pace. Although the economic environment is showing gradual signs of recovery, the volume of higher value-added projects has not yet reached the level envisaged in our targets. Compared to the strong comparative base of the previous year, profitability remained more modest; however, the growth in the order book and improved utilization of production capacity provide grounds for a more positive outlook for the coming periods.

At the same time, we see encouraging developments in the gradual improvement of profitability compared to the first half of the year and the continued strengthening of the order book. Order intake growth is being driven primarily by strong investment activity in the data centre sector and the resulting demand for more advanced power distribution solutions. During the third quarter, we signed a contract worth approximately 15.5 million euros for the design and manufacture of E-house solutions for the electrical distribution system of a data centre being developed in Finland. E-house solutions integrate power distribution and control systems into a factory-built modular solution, reducing the amount of on-site work and shortening overall project implementation time. Demand is further supported by trends in the technology sector, including the rapid adoption of artificial intelligence applications, ongoing digitalisation, and electrification, all of which are driving the need for more reliable and higher-capacity electrical infrastructure solutions. We believe that the combined impact of these developments is creating an attractive long-term growth market for Harju Elekter and will continue to support the strengthening of our order book.

To support the increasing project volumes driven by growing demand from the data centre sector, a new 4,000-square-metre production facility was completed in Keila at the end of the quarter. The new factory expansion will manufacture electrical equipment and power control solutions for data centres, which will be exported to customers across Europe and other global markets. This investment significantly enhances our production capacity and supports the Group’s long-term growth strategy in the rapidly expanding data centre market.

To support the growing order book, we are increasingly managing the Group’s manufacturing network as an integrated whole. We are already seeing higher utilisation levels in our Estonian production units, and one of our key priorities is therefore to increase capacity utilisation at the Lithuanian factory and involve it more extensively in fulfilling the Group’s order backlog. At the same time, we are actively working to broaden the Lithuanian unit’s customer and product portfolio. While its activities have historically been focused largely on customers in the marine sector, our aim is to increase its presence in other market segments going forward. This is supported by the growing expertise of the Lithuanian team, which has been strengthened through participation in projects across other Harju Elekter units. For several ongoing tenders and projects, we already see opportunities to allocate additional production volumes to Lithuania, thereby improving the Group’s overall resource utilisation and creating a more balanced workload across our manufacturing units.

In addition, we continue to transform our operations in Finland. The contract manufacturing market has become increasingly competitive in recent years, and the traditional model based primarily on selling production capacity and labour hours is no longer sustainably competitive in a high-cost environment over the long term. As a result, we have decided to gradually reduce the share of lower value-added contract manufacturing and reallocate resources toward higher-margin project business. Our focus is on larger customers and projects where we can make better use of our engineering expertise and create greater value for our customers.

During the third quarter, we implemented changes in the Group’s leadership. The order book of our Swedish business unit has grown significantly in recent years, while market prospects remain favourable, supported by ongoing investments in electricity grid infrastructure. To support the next phase of development, we appointed Jan Kotka as the new Managing Director of our Swedish subsidiary. Jan brings extensive international experience in leading industrial companies and executing strategic transformation initiatives. The objective of the leadership change is to support sustainable profitability, improve operational efficiency, and strengthen collaboration across the Group.

A significant event also took place after the end of the quarter, when Harju Elekter accepted an offer from Siemens International Holding B.V. for the partial disposal of its shareholding in OÜ Skeleton Technologies Group. The transaction enables us to realise part of the value created by an investment made nearly a decade ago, recover the full amount of the original investment together with a reasonable return, and increase the Group’s financial flexibility. At the same time, we remain a shareholder in Skeleton and see potential to realise the remaining investment in the future under appropriate conditions.

Despite the challenges that remain, the Group’s key performance indicators are moving in the desired direction. A strengthening order book, improving profitability, increased production capacity, and favourable market trends driven by electrification and demand from the data centre sector give us confidence that Harju Elekter is well positioned for its next phase of growth. We will continue to focus on improving capacity utilisation across our manufacturing network, strengthening our order book, and developing the organisation, while looking to the future with cautious optimism.

Revenue and financial results

The Group’s revenue amounted to 41.0 (Q3 2025: 43.0) million euros in the third quarter and 118.2 (9M 2025: 126.5) million euros in the nine months. There are signs of improvement – total volume remained below the previous year’s level, but the decline slowed and sales shifted towards the growing Nordic markets. Growth was driven by the Finnish and Swedish markets, which significantly increased their share of the Group’s sales.

EUR’000		Q3	Q3	+/-	9M	9M	+/-
		2026	2025		2026	2025
Revenue		40,967	43,034	-4.8%	118,190	126,531	-6.6%
Gross profit		6,821	7,461	-8.6%	17,482	20,564	-15.0%
EBITDA		3,486	4,840	-28.0%	7,392	13,364	-44.7%
Operating profit (EBIT)		2,322	3,759	-38.2%	3,910	10,139	-61.4%
Profit for the period		1,314	2,898	-54.7%	1,605	8,161	-80.3%
Earnings per share (EPS) (euros)		0.07	0.16	-56.3%	0.09	0.44	-79.5%

The Group’s operating expenses amounted to 38.6 (Q3 2025: 39.4) million euros in the third quarter and 114.5 (9M 2025: 117.4) million euros in the nine months, decreasing by 2.0% and 2.5%, respectively. The majority of operating expenses consisted of the cost of sales.

Distribution costs increased to 2.1 (Q3 2025: 1.7) million euros in the third quarter and 5.8 (9M 2025: 4.4) million euros in the nine months. The increase is related to strategic investments in sales and marketing activities, including participation in international trade fairs and strengthening of sales teams, with the aim of laying the foundation for a recovery in sales volumes in future periods.

Administrative expenses increased by 12.7% to 2.3 (Q3 2025: 2.1) million euros in the quarter and by 13.5% to 8.0 (9M 2025: 7.0) million euros in the nine months, accounting for 6.7% (9M 2025: 5.5%) of nine-month revenue.

Labour costs increased by 9.0% to 9.2 (Q3 2025: 8.5) million euros in the third quarter and by 8.8% to 30.6 (9M 2025: 28.1) million euros in the nine months, of which wages and salaries amounted to 8.0 (Q3 2025: 7.2) and 24.6 (9M 2025: 21.8) million euros, respectively. Labour costs as a percentage of revenue rose to 22.5% (Q3 2025: 19.7%) in the third quarter and to 25.9% (9M 2025: 22.2%) in the nine months, as the Group retained its team and production capacity to serve upcoming project volumes.

Gross profit decreased to 6.8 (Q3 2025: 7.5) million euros and the gross margin fell to 16.6% (Q3 2025: 17.3%). The decline in margin was mainly due to lower production volumes, which resulted in weaker coverage of fixed costs. Third-quarter operating profit (EBIT) amounted to EUR 2.3 million (Q3 2025: EUR 3.8 million), resulting in an operating margin of 5.7% (Q3 2025: 8.7%). Gross profit for nine months was 17.5 (9M 2025: 20.6) million euros and the gross margin 14.8% (9M 2025: 16.3%), operating profit (EBIT) 3.9 (9M 2025: 10.1) million euros. The operating margin for nine months was 3.3% (9M 2025: 8.0%). Net profit for the nine months was 1.6 (9M 2025: 8.2) million euros.

Core business and markets

The most significant change took place by markets: the Group’s sales are increasingly concentrated in Finland and Sweden. These two markets accounted for 60.1% (Q3 2025: 41.7%) of the Group’s revenue in the third quarter.

Revenue in Finland amounted to 17.0 (Q3 2025: 13.7) million euros in the third quarter and 48.1 (9M 2025: 40.4) million euros in the nine months. Nine-month sales increased by 19.0% and Finland’s share of the Group’s revenue rose to 40.7% (9M 2025: 31.9%). Growth was supported by stable deliveries of electrical distribution solutions, particularly compact secondary substations and low-voltage switchgear.

Sweden recorded the strongest growth among the markets, with revenue of 7.6 (Q3 2025: 4.2) million euros in the quarter and 21.6 (9M 2025: 14.4) million euros in the nine months, an increase of 50.8% over the nine months. Sales were supported by the realisation of larger projects and demand for substations and technical buildings.

In the third quarter, sales decreased in Norway, Estonia and the Netherlands, mainly due to the high comparison base: in the previous year, sales in these markets were shaped by individual large projects whose timing has changed. Revenue in Norway amounted to 5.0 (Q3 2025: 10.7) million euros in the quarter and 14.8 (9M 2025: 28.2) million euros in the nine months, decreasing by 53.0% and 47.4%, respectively. Revenue in Estonia amounted to 4.6 (Q3 2025: 8.7) million euros in the quarter and 14.7 (9M 2025: 20.6) million euros in the nine months, decreasing by 47.1% and 28.5%, respectively. The decline was affected by the timing of orders related to distribution networks, while part of the production volume was directed at fulfilling Scandinavian contracts. As a positive sign, the Group’s sales are expanding into new and smaller markets.

Investments

During the nine months, the Group invested 5.5 (9M 2025: 2.9) million euros in non-current assets, almost twice as much as a year earlier. Of this amount, 4.4 (9M 2025: 1.2) million euros was invested in property, plant and equipment, 1.1 (9M 2025: 1.4) million euros in intangible assets and 0.04 (9M 2025: 0.3) million euros in investment property.

The largest investment was the new 4,000 m² production building in Keila, which increased the total production area of the Keila factories to 30,000 m². The new factory produces electrical equipment and control solutions for data centres, supporting the Group’s growth in this strategically important sector. In addition, production equipment was acquired to increase production capacity and improve process efficiency. In Finland, production was consolidated in Ulvila and the 850 m² Kerava production building was sold during the reporting period. Investments in intangible assets were mainly related to the development of the next-generation electric vehicle charger Elektra Sense and the Group’s digital solutions. The value of long-term financial investments remained at 27.2 (31.12.25: 27.2) million euros.

Share

The company’s share price on the last trading day of the reporting quarter on the Nasdaq Tallinn Stock Exchange closed at 5.16 euros.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
Unaudited
EUR ‘000	30.09.2026		31.12.2025		30.09.2025
ASSETS
Current assets
Cash and cash equivalents	1,484		1,545		2,698
Trade and other receivables	35,586		46,654		45,350
Prepayments	2,321		1,209		1,846
Inventories	25,761		19,896		26,689
Total current assets	65,152		69,304		76,583
Non-current assets
Deferred income tax assets	124		142		529
Non-current financial investments	27,217		27,225		27,234
Non-current receivables	2		9		0
Investment properties	27,103		28,228		28,564
Property, plant, and equipment	35,042		33,273		32,102
Intangible assets	10,624		9,880		9,342
Total non-current assets	100,112		98,757		97,771
TOTAL ASSETS	165,264		168,061		174,354
LIABILITIES AND EQUITY
Liabilities
Borrowings	12,156		15,452		12,857
Prepayments from customers	9,228		15,326		13,739
Trade and other payables	23,184		19,670		26,191
Tax liabilities	3,505		3,324		4,573
Current provisions	297		336		464
Total current liabilities	48,370		54,108		57,824
Borrowings	20,081		15,072		19,939
Other non-current liabilities	20		20		17
Total non-current liabilities	20,101		15,092		19,956
TOTAL LIABILITIES	68,471		69,200		77,780
Equity
Share capital	11,706		11,672		11,672
Share premium	3,619		3,410		3,410
Reserves	23,053		22,397		22,965
Retained earnings	58,415		61,382		58,527
Total equity attributable to the owners of the parent company	96,793		98,861		96,574
TOTAL LIABILITIES AND EQUITY	165,264		168,061		174,354

CONSOLIDATED STATEMENT OF PROFIT AND LOSS
Unaudited
EUR ‘000		Q3		Q3		9M		9M
		2026		2025		2026		2025
Revenue		40,967		43,034		118,190		126,531
Cost of sales		-34,146		-35,573		-100,708		-105,967
Gross profit		6,821		7,461		17,482		20,564
Distribution costs		-2,111		-1,748		-5,834		-4,429
Administrative expenses		-2,323		-2,062		-7,951		-7,007
Other income		186		145		859		1,175
Other expenses		-251		-37		-646		-164
Operating profit		2,322		3,759		3,910		10,139
Finance income		119		226		258		1,125
Finance costs		-975		-392		-2,285		-1,743
Profit before tax		1,466		3,593		1,883		9,521
Income tax		-152		-695		-278		-1,360
Profit for the period		1,314		2,898		1,605		8,161
Earnings per share
Basic earnings per share (euros)		0.07		0.16		0.09		0.44
Diluted earnings per share (euros)		0.07		0.16		0.09		0.44

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
Unaudited
EUR ‘000	Q3	Q3		9M		9M
	2026	2025		2026		2025
Profit for the period	1,314	2,898		1,605		8,161
Other comprehensive income
Items that may be reclassified to profit or loss
Impact of exchange rate changes of foreign subsidiaries	330	-9		735		-376
Items that will not be reclassified to profit or loss
Realized gain on sales of financial assets	0	0		0		385
Revaluation of financial assets	-6	14		-6		8
Total other comprehensive income (-loss) for the period	324	5		729		17
Total comprehensive income	1,638	2,903		2,334		8,178

Priit Treial
CFO and Member of the Management Board

priit.treial@harjuelekter.com
+372 674 7400

Attachment

• HEG interim report Q3 2026

CALGARY, Alberta, Oct. 21, 2026 (GLOBE NEWSWIRE) — Pulse Seismic Inc. (TSX:PSD) (OTCQX:PLSDF) (“Pulse” or the “Company”) is pleased to report its financial and operating results for the three and nine months ended September 30, 2026. The unaudited condensed consolidated interim financial statements, accompanying notes and MD&A are being filed on SEDAR+ (www.sedarplus.ca) and will be available on Pulse’s website at www.pulseseismic.com.

Today, Pulse’s Board of Directors declared a regular quarterly dividend of $0.01875 per common share. The total of the dividend will be approximately $951,000 based on Pulse’s 50,708,857 common shares outstanding as of October 21, 2026, to be paid on November 18, 2026, to shareholders of record on November 4, 2026. This dividend is designated as an eligible dividend for Canadian income tax purposes. For non-resident shareholders, Pulse’s dividends are subject to Canadian withholding tax.

“Our third quarter results demonstrate the strength of Pulse’s business model and the value of our strategically positioned seismic data library,” stated Pamela Wicks, Pulse’s President and CEO. “Revenue of $17.3 million in the quarter drove shareholder free cash flow of $11.5 million, highlighting our ability to convert licensing activity into meaningful cash flow. Improving industry fundamentals support ongoing demand for high-quality seismic in prolific areas of oil and gas development. With a debt-free balance sheet, strong liquidity and a continued focus on capital discipline, Pulse is well positioned to leverage its assets and capitalize on opportunities to deliver value to shareholders,” concluded Wicks.

“As disclosed in August, the Company appointed Pamela Wicks as Pulse’s President and Chief Executive Officer. I am excited about the management change at Pulse. The Board and I have high conviction in the potential value to be realized through the active management of our seismic data library, which was acquired over decades at a historical cost of over $500 million,” added Robert Robotti, Pulse Board Chair.

HIGHLIGHTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026

• Total revenue for the third quarter of 2026 was $17.3 million, as compared to $3.4 million for the same period in 2025. Total revenue for the first nine months of 2026 was $22.8 million, as compared to $44.5 million last year.
   
• EBITDA^(a) for the third quarter of 2026 was $14.7 million ($0.29 per share basic and diluted), compared to $744,000 ($0.01 per share basic and diluted) for the same period in 2025. For the first nine months of 2026, EBITDA^(a) was $15.3 million as compared to $36.0 million for the same period last year. The significant increase in EBITDA over the sequential quarter is due to strong revenue activity realized in the third quarter of 2026 combined with the Company’s disciplined cost structure and ability to effectively manage periods of revenue fluctuations.
   
• Shareholder free cash flow^(a) was $11.5 million ($0.23 per share basic and diluted) in the third quarter of 2026, as compared to $571,000 ($0.01 per share basic and diluted) for the same period in 2025. For the first nine months of 2026, shareholder free cash flow^(a) was $12.5 million ($0.25 per share basic and diluted) compared to $27.7 million ($0.55 per share basic and diluted) for the same period in 2025.
   
• In the third quarter of 2026, the Company generated net earnings of $11.4 million ($0.22 per share basic and diluted), as compared to a net loss of $1.5 million ($0.03 per share basic and diluted) for the same period in 2025. For the first nine months of 2026, net earnings were $11.5 million ($0.23 per share basic and diluted) compared to $21.4 million ($0.42 per share basic and diluted) for the same period last year.
   
• At September 30, 2026, the Company exited the third quarter of 2026 with $20.9 million of positive working capital, including $8.7 million of cash. The Company also had $5.0 million of available liquidity on its credit facility.
   
• Total dividends declared and paid in the third quarter of 2026 was $951,000 ($0.01875 per share). For the first nine months of 2026, total dividends declared and paid was $7.9 million ($0.15500 per share). This includes three regular quarterly dividends and one special dividend.

SELECTED FINANCIAL AND OPERATING INFORMATION
				Three months ended September 30,			Nine months ended September 30,			Year ended December 31,
(Thousands of dollars except per share data,				2026	2025		2026		2025	2025
numbers of shares and kilometres of seismic data)				(unaudited)			(unaudited)			(audited)
Revenue				17,308	3,416		22,765		44,491	51,090
Amortization of seismic data library				8	2,225		400		6,674	8,898
Net (loss) earnings				11,354	(1,500	)	11,549		21,440	23,119
Per share basic and diluted				0.22	(0.03	)	0.23		0.42	0.46
Cash (used in) provided by operating activities				1,286	1,271		(3,050	)	30,429	35,204
Per share basic and diluted				0.03	0.03		(0.06	)	0.60	0.69
EBITDA (a)				14,747	744		15,290		36,030	40,847
Per share basic and diluted (a)				0.29	0.01		0.30		0.71	0.80
Shareholder free cash flow (a)				11,485	571		12,545		27,723	31,596
Per share basic and diluted (a)				0.23	0.01		0.25		0.55	0.62
Dividends
Regular dividends declared				951	889		2,790		2,537	3,425
Special dividends declared				–	10,151		5,071		20,318	20,318
Total dividends declared				951	11,040		7,861		22,855	23,743
Normal course issuer bid
Number of shares purchased and cancelled				6,000	–		6,000		80,600	120,800
Cost of shares purchased and cancelled				17	–		17		197	309
Weighted average shares outstanding
Basic and diluted				50,712,216	50,755,057		50,713,967		50,781,655	50,770,625
Shares outstanding at period-end							50,708,857		50,755,057	50,714,857
Seismic library
2D in kilometres							829,207		829,207	829,207
3D in square kilometres							65,310		65,310	65,310
FINANCIAL POSITION
							September 30,		September 30,	December 31,
(Thousands of dollars except working capital ratio)							2026		2025	2025
Working capital							20,869		14,001	16,792
Working capital ratio							4.8:1		3.8:1	4.9:1
Cash and cash equivalents							8,685		16,068	19,746
Total assets							27,052		22,796	22,732
Trailing 12-month (TTM) EBITDA (b)							20,107		39,815	40,847
Shareholders’ equity							20,954		16,637	17,316

(a) The Company’s continuous disclosure documents provide discussion and analysis of “EBITDA”, “EBITDA per share”, “shareholder free cash flow” and “shareholder free cash flow per share”. These financial measures do not have standard definitions prescribed by IFRS and, therefore, may not be comparable to similar measures disclosed by other companies. The Company has included these non-GAAP financial measures because management, investors, analysts and others use them as measures of the Company’s financial performance. The Company’s definition of EBITDA is cash available for interest payments, cash taxes, repayment of debt, purchase of its shares, discretionary capital expenditures and the payment of dividends, and is calculated as earnings or loss from operations before interest, taxes, depreciation and amortization. The Company believes EBITDA assists investors in comparing Pulse’s results on a consistent basis without regard to non-cash items, such as depreciation and amortization, which can vary significantly depending on accounting methods or non-operating factors such as historical cost. EBITDA per share is defined as EBITDA divided by the weighted average number of shares outstanding for the period. Shareholder free cash flow further refines the calculation of capital available to invest in growing the Company’s 2D and 3D seismic data library, to repay debt, to purchase its common shares and to pay dividends by deducting non-discretionary expenditures from EBITDA. Non-discretionary expenditures are defined as non-cash expenses, debt financing costs (net of deferred financing expenses amortized in the current period), net restructuring costs and current tax provisions. Shareholder free cash flow per share is defined as shareholder free cash flow divided by the weighted average number of shares outstanding for the period.
These non-GAAP financial measures are defined, calculated and reconciled to the nearest GAAP financial measures in the Management’s Discussion and Analysis.
(b) TTM EBITDA is defined as the sum of EBITDA generated over the previous 12 months and is used to provide a comparable annualized measure. These non-GAAP financial measures are defined, calculated and reconciled to the nearest GAAP financial measures in the Management’s Discussion and Analysis.

CORPRATE OUTLOOK AND BUSINESS ENVIRONMENT

Pulse’s business and financial outlook is shaped by industry conditions and regulatory developments that have materially improved the investment environment for Canadian oil and gas exploration and production. Recent infrastructure capacity additions, accelerating upstream activity, and strengthened federal policy support suggest improving near-term demand for the Company’s subsurface seismic data assets.

Positive Industry Indicators
Several developments support increased E&P capital deployment and exploration activity:

• Land market activity: Alberta land sales in the first nine months of 2026 reached $224.5 million, representing a 14% increase from $197.2 million in the prior year, reflecting renewed producer confidence and capital allocation to exploration.
• Drilling acceleration: Drilling activity has outpaced 2026 forecasts, with the Canadian Association of Energy Contractors reporting very strong year-to-date activity driven by higher oil prices and increased capital expenditures on exploration and production. The Association now expects its initial December 2025 forecast of 5,709 wells to be exceeded during the fourth quarter.
• Infrastructure capacity expansion: Two significant developments address historical production constraints:
  • The TMX pipeline reached its full 890,000 bpd capacity by Q2 2026, reflecting sustained demand for Canadian crude.
  • TC Energy’s Coastal GasLink Phase 2 pipeline was approved in September 2026 and will double pipeline capacity to transport natural gas from northern British Columbia to LNG Canada’s liquefaction facility in Kitimat.
• LNG sector growth: LNG Canada has been operational for over a year and reached full capacity through 2026, contributing to expanded Canadian energy exports. The facility has announced phase 2 approval, adding 12 million metric tons per year of offtake capacity. The approved Ksi Lisims LNG development in coastal British Columbia will add an additional 12 million mt/year of export capacity, positioning Canada as a larger global LNG supplier and supporting longer-term investment returns to the exploration sector.
• M&A acceleration: Industry M&A activity in 2026 is significantly outpacing forecasts. Early year estimates projected $15 billion; by the end of Q3, activity had already doubled this amount with continued momentum expected through year-end. This suggests heightened strategic consolidation and capital redeployment within the sector.

Improved Policy Environment
Federal government support for energy infrastructure has accelerated:

• The Building Canada Act (2025) established a streamlined regulatory review process for designated national interest projects. On October 1, 2026, the government designated the Pacific Link Pipeline as Canada’s first project under this framework. Pacific Link will add up to 1 million barrels per day of oil export capacity via a West Coast deepwater port, reducing Canada’s dependence on U.S.-bound pipeline capacity and enabling access to higher-value Asian markets.
• The inaugural Canada Investment Summit (September 2026) convened approximately 300 institutional investors collectively managing over $120 trillion in assets, signaling heightened international capital interest in Canadian energy infrastructure and nation-building projects.

Outlook
The convergence of improved policy certainty, removal of infrastructure bottlenecks, accelerating upstream activity indicators, and mobilized global capital provides a materially more supportive environment for exploration and development spending in Western Canada. Increased E&P activity and production expansion projects typically drive demand for subsurface seismic data to inform drilling programs, development planning, and reserves estimation.

The Company continues to monitor significant factors that could affect the business, including global geopolitical tensions, U.S.-Canada trade policy developments, and instability in the Middle East. Commodity price volatility, potential delays in major project timelines, and discretionary procurement decisions by E&P customers could materially impact exploration spending and demand for seismic data services. Additionally, long-cycle project investment decisions may not advance as anticipated.

Strategic Position
Pulse is well-positioned to benefit from this improved environment through a strong balance sheet with no debt, experienced management, and a disciplined low-cost operating model. These fundamentals, combined with high EBITDA leverage to revenue growth and prudent capital management, enable the Company to pursue strategic opportunities and deliver consistent shareholder returns.

CORPORATE PROFILE

Pulse is a market leader in the acquisition, marketing and licensing of 2D and 3D seismic data to the western Canadian energy sector. Pulse owns the largest licensable seismic data library in Canada, currently consisting of approximately 65,310 square kilometres of 3D seismic and 829,207 kilometres of 2D seismic. The library extensively covers the Western Canada Sedimentary Basin, where most of Canada’s oil and natural gas exploration and development occur.

For further information, please contact:
Pamela Wicks, President and CEO
Tel.: 403-237-5559
Toll-free: 1-877-460-5559
E-mail: info@pulseseismic.com.
Please visit our website at www.pulseseismic.com

This document contains information that constitutes “forward-looking information” or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities legislation. Forward-looking information is often, but not always, identified by the use of words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “forecast”, “target”, “project”, “guidance”, “may”, “will”, “should”, “could”, “estimate”, “predict”, “potential” or similar words suggesting future outcomes or language suggesting an outlook.

The Outlook section herein contain forward-looking information which includes, but is not limited to, statements regarding:

• The outlook of the Company for the year ahead, including future operating costs and expected revenues;
• Recent events on the political, economic, regulatory, and legal fronts affecting the industry’s medium- to longer-term prospects, including progression and completion of contemplated pipeline projects;
• The Company’s capital resources and sufficiency thereof to finance future operations, meet its obligations associated with financial liabilities and carry out the necessary capital expenditures through 2026;
• Pulse’s capital allocation strategy;
• Pulse’s dividend policy;
• Oil and natural gas prices and forecast trends;
• Oil and natural gas drilling activity and land sales activity;
• Oil and natural gas company capital budgets;
• Future demand for seismic data;
• Future seismic data sales;
• Pulse’s business and growth strategy; and
• Other expectations, beliefs, plans, goals, objectives, assumptions, information and statements about possible future events, conditions, results and performance, as they relate to the Company or to the oil and natural gas industry as a whole

By its very nature, forward-looking information involves inherent risks and uncertainties, both general and specific, and risks that predictions, forecasts, projections and other forward-looking statements will not be achieved. Pulse does not publish specific financial goals or otherwise provide guidance, due to the inherently poor visibility of seismic revenue. The Company cautions readers not to place undue reliance on these statements as a number of important factors could cause the actual results to differ materially from the beliefs, plans, objectives, expectations and anticipations, estimates and intentions expressed in such forward-looking information.

These factors include, but are not limited to:

• Uncertainty of the timing and volume of data sales;
• Volatility of oil and natural gas prices;
• Risks associated with the oil and natural gas industry in general;
• The Company’s ability to access external sources of debt and equity capital;
• Credit, liquidity and commodity price risks;
• The demand for seismic data;
• The pricing of data library licence sales;
• Cybersecurity;
• Relicensing (change-of-control) fees and partner copy sales;
• Environmental, health and safety risks;
• Federal and provincial government laws and regulations, including those pertaining to taxation, royalty rates, environmental protection, public health and safety;
• Competition and the regulation thereof;
• Dependence on key management, operations and marketing personnel;
• The loss of seismic data;
• Protection of intellectual property rights;
• The introduction of new products; and
• Climate change.

Pulse cautions that the foregoing list of factors that may affect future results is not exhaustive. Additional information on these risks and other factors which could affect the Company’s operations and financial results is included under “Risk Factors” in the Company’s most recent annual information form, and in the Company’s most recent audited annual financial statements, most recent MD&A, management information circular, quarterly reports, material change reports and news releases. Copies of the Company’s public filings are available on SEDAR+ at www.sedarplus.ca.

When relying on forward-looking information to make decisions with respect to Pulse, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Furthermore, the forward-looking information contained in this document is provided as of the date of this document and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, except as required by law. The forward-looking information in this document is provided for the limited purpose of enabling current and potential investors to evaluate an investment in Pulse. Readers are cautioned that such forward-looking information may not be appropriate, and should not be used, for other purposes.

PDF available: http://ml.globenewswire.com/Resource/Download/474a5c46-8ee2-425e-a5f0-31d61e8a532c

New capability delivers a 70% sulfuric acid recycle rate while maintaining stringent particle control; System validated across more than 50 process layers at a foundry customer

FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) — ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer processing solutions for semiconductor and advanced packaging applications, today announced an enhanced version of its 170°C Single-Wafer Hot Sulfuric Peroxide Mixture (“SPM”) system featuring a new sulfuric acid recycle capability. The system has been validated by a foundry customer across more than 50 process layers, demonstrating its ability to support a broad range of cleaning applications.

ACM’s Single-Wafer Hot SPM system achieves particle counts of 15 or fewer at 15 nm and above, significantly outperforming mainstream market solutions. Unlike conventional systems that require periodic deionized (“DI”) water rinsing to remove crystalline deposits caused by acid mist during hot SPM processing, ACM’s proprietary nozzle design effectively prevents such contamination, enabling stable cleaning performance without periodic DI water chamber cleaning. This design can help improve yields in both logic and memory applications while reducing equipment maintenance requirements.

The new sulfuric acid recycle capability achieves a 70% sulfuric acid recycle rate while maintaining particle control performance as demanded by customer specifications. The innovation is expected to save approximately 400 tons of sulfuric acid per tool annually, thus delivering significant environmental and cost benefits while meeting the stringent process requirements of semiconductor manufacturing.

“As semiconductor manufacturing becomes more complex, customers need technologies that can meet increasingly demanding process requirements while improving manufacturing efficiency,” said Dr. David Wang, President and Chief Executive Officer of ACM. “The continued advancement and customer validation of our Single-Wafer Hot SPM platform demonstrates ACM’s commitment to differentiated innovation and our ability to deliver solutions that address the evolving needs of semiconductor manufacturers.”

SPM is widely used in semiconductor manufacturing for photoresist stripping, organic polymer residue removal, metallic impurity and particle removal, and post-CMP cleaning. As semiconductor manufacturing processes become increasingly complex, manufacturers must balance demanding cleaning and particle-control requirements with the need to manage chemical consumption and operating efficiency. ACM’s Single-Wafer Hot SPM system is designed to address these requirements through single-wafer processing and differentiated process and chamber design.

The new sulfuric acid recycle capability further enhances the efficiency of ACM’s Single-Wafer Hot SPM platform. By recovering and reusing a significant portion of the sulfuric acid used during processing while maintaining particle control, the system enables manufacturers to reduce chemical consumption without compromising process performance. Validation across more than 50 process layers at the customer site further demonstrates the platform’s ability to support a broad range of cleaning applications.

Forward-Looking Statements

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plans,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. Forward-looking statements are based on ACM management’s current expectations and beliefs and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings ACM makes with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by ACM. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. ACM undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

About ACM Research, Inc.

ACM develops, manufactures and sells semiconductor process equipment spanning cleaning, electroplating, stress-free polishing, vertical furnace processes, track, PECVD, and wafer- and panel-level packaging tools, enabling advanced and semi-critical semiconductor device manufacturing. ACM is committed to delivering customized, high-performance, cost-effective process solutions that semiconductor manufacturers can use in numerous manufacturing steps to improve productivity and product yield. For more information, visit www.acmr.com.

© ACM Research, Inc. The ACM Research logo is a trademark of ACM Research, Inc. For convenience, the trademark appears in this press release without the ™ symbol, but that practice does not mean ACM will not assert, to the fullest extent under applicable law, its rights to such trademarks. All other trademarks are the property of their respective owners.

Media Contact:	Company Contacts:
Alyssa Lundeen	USA
Bodewell Group	Robert Metter
+1 218.398.0776	+1 503.367.9753
alundeen@bodewellgroup.com
	China
	Xi Wang
IR Contacts:	ACM Research (Shanghai), Inc.
The Blueshirt Group	+86 21 50808868
Steven C. Pelayo, CFA
+1 360.808.5154	Korea
steven@blueshirtgroup.co	ACM Research (Korea), Inc.
	+82 70-41006699
Gary Dvorchak, CFA
+86 138.1079-1480	Taiwan
gary@blueshirtgroup.co	David Chang
	+886 921999884
	Singapore
	Adrian Ong
	+65 8813-1107

Resolute implementation of RENK Group strategic realignment with sale of slide bearings business to Miba AG RENK underscores sector strategy announced in late 2025 with this transaction Transaction has no impact on Marine & Industry’s civil business Augsburg, October 22, 2026 – RENK Group AG, a leading provider of propulsion solutions for the military and civilian sectors, is to sell its slide bearings business to Miba AG. Miba is an Austrian industrial and technology company that operates worldwide. Its slide bearings business, Miba Bearing Group, specializes in developing and producing slide bearing technologies for industrial applications and slide bearing. Systematic focus on core defense business “We are realizing our sector strategy as announced with the sale of the slide bearings business, by placing an even sharper strategic focus on the defense business,” said CEO of RENK Group AG Dr. Alexander Sagel. “I am also delighted to have found exactly the right partner for the technologically strong slide bearings business in Miba, in order to develop Slide Bearings with the appropriate sector focus,” Sagel continued. “In terms of expertise, Miba and RENK’s slide bearings business are an excellent match. Through the sale, we aim to pool and strengthen our expertise,” underscores F. Peter Mitterbauer, CEO of Miba AG. “We will be in an even better position to offer our customers unique slide bearing technologies for the energy transition and electrification, for example, for feeding wind and solar power into power grids, supplying data centers with power for artificial intelligence, for electric motors, or for clean and secure naval gear systems.” The RENK Group plans to increase the share of defense business in the company’s total revenue to around 90 percent by 2030. The sale of the Slide Bearings business enables the company to focus capital and capacities even more strongly on the growth markets for defense solutions on land and at sea. The transaction has no impact on the civilian business within the Marine & Industry (M&I) division. This business is tightly integrated with defense in terms of production and, at the same time, offers attractive growth prospects in the areas of power generation and infrastructure. The products manufactured by the Slide Bearings division comprise standardized slide bearings for electric motors, generators and pumps, and are used primarily in industrial and civilian markets. The slide bearings business is located at the Hanover site and has been operated as an independent company named RENK Bearings GmbH since October 2025. As a result of the sale, the Slide Bearings business unit will be reported as a discontinued operation in accordance with IFRS 5 beginning in the fourth quarter of 2026. The RENK Group will therefore report its guidance in the future exclusively on the basis of continuing operations. These include the Vehicle Mobility Solutions (VMS) and M&I divisions. This results in the following updated guidance for the fiscal year 2026 for revenue of ~€1.4 billion and for adjusted EBIT from €240 million to €255 million. The parties have agreed to keep the purchase price confidential. The transaction is subject to the customary regulatory approvals. About the RENK Group AG Headquartered in Augsburg, Germany, RENK Group AG is a globally leading manufacturer of mission-critical propulsion solutions across diverse military and civil end markets. Our product portfolio includes gear units, transmissions, power-packs, hybrid propulsion systems, suspension systems, slide bearings, couplings & clutches and test systems. With this broad product portfolio RENK Group AG serves, in particular, customers in industries for military vehicles, naval, civil marine, and industrial applications focused on energy. In the fiscal year 2025, RENK Group AG generated revenue of approximately EUR 1.4 billion. RENK Group AG has been listed on the Frankfurt Stock Exchange since February 7, 2024, and has been a member of the MDAX since March 24, 2025. For further information, please visit www.renk.com About Miba AG Miba AG is one of Austria’s leading industrial and technology companies. It is represented in all important customer markets worldwide with 30 production sites in Europe, Asia, and North and South America, and has around 7,400 employees. Miba develops and produces functionally critical components along the entire energy value chain. Its products make an important contribution to the efficient and sustainable generation, transmission, storage, and use of energy. Miba bearings, powder metal parts, friction materials, power electronics components, and coatings are used around the world in applications like wind power turbines and hydropower plants, power grids, vehicles, ships, aircraft, and agricultural and construction machinery. Miba’s revenue in fiscal year 2025/26 amounted to more than €1.2 billion The company generated 62 percent of its revenue in the industrial goods sector and 38 percent in the automotive segment. For more information, please visit www.miba.com. Disclaimer This Press Release contains forward-looking statements that are based on plans, expectations, estimates and projections of the management of RENK Group as at the date of this Press Release. These plans, expectations, estimates and projections depend on a variety of assumptions and are subject to unforeseeable events, uncertainties, known and unknown risks as well as other factors that may cause actual results or the actual financial situation, development or performance to differ from those expressed or implied in the forward-looking statements. RENK Group does not assume any obligation to update the forward-looking statements or make adjustments to them to reflect events or developments occurring after the date of this Press Release unless obliged by statutory law.

RENK Group AG Gögginger Str. 73 D-86159 Augsburg Deutschland  www.renk.com	Media Inquiries to: Fabian Klee Chief Communications and Marketing Officer fabian.klee@renk.com +49 160 7154 647	Investor Inquiries to: Team Investor Relations investors@renk.com
About the RENK Group AG Headquartered in Augsburg, Germany, RENK Group AG is a globally leading manufacturer of mission-critical propulsion solutions across diverse military and civil end markets. Our product portfolio includes gear units, transmissions, power-packs, hybrid propulsion systems, suspension systems, slide bearings, couplings & clutches and test systems. With this broad product portfolio RENK Group AG serves, in particular, customers in industries for military vehicles, naval, civil marine, and industrial applications focused on energy. In the fiscal year 2025, RENK Group AG generated revenue of approximately EUR 1.4 billion. RENK Group AG has been listed on the Frankfurt Stock Exchange since February 7, 2024, and has been a member of the MDAX since March 24, 2025.   For further information, please visit www.renk.com   Disclaimer This Press Release contains forward-looking statements that are based on plans, expectations, estimates and projections of the management of RENK Group as at the date of this Press Release. These plans, expectations, estimates and projections depend on a variety of assumptions and are subject to unforeseeable events, uncertainties, known and unknown risks as well as other factors that may cause actual results or the actual financial situation, development or performance to differ from those expressed or implied in the forward-looking statements. RENK Group does not assume any obligation to update the forward-looking statements or make adjustments to them to reflect events or developments occurring after the date of this Press Release unless obliged by statutory law.

Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO

Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027

ROCKVILLE, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) — Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) has recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.

The seven-year market exclusivity for ONAPGO began on February 3, 2025, the date of FDA approval. The FDA’s Orphan Drug Designation program is designed to advance the development of drugs that treat a condition affecting 200,000 or fewer U.S. patients annually.

In addition, the Company submitted a supplemental New Drug Application (sNDA) to the FDA for a second supplier for ONAPGO and continues to expect potential FDA approval of the second supplier by mid-year 2027.

“Securing orphan-drug exclusivity marks an important milestone for individuals and families navigating Parkinson’s disease. This designation validates the urgent need for targeted therapies and helps safeguard continued innovation in a long-underserved community,” said Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “In addition to resolving the supply issue from earlier this year, submitting our sNDA further reinforces our ongoing commitment to providing novel treatments for patients with Parkinson’s disease, backed by our unwavering focus on ensuring an uninterrupted drug supply for every patient in need.”

More information about ONAPGO, including Full Prescribing Information and Medication Guide, is available here: www.onapgo.com.

About Supernus, Inc.

Supernus, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.

For more information, please visit www.supernus.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management’s current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase its net revenue from its products and the products of its subsidiaries; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates or manufacture ONAPGO at the second supplier; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products, including ONAPGO, and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

Supernus, Inc. Contacts

Jack A. Khattar, President and CEO
Tim Dec, Senior Vice President and CFO
Supernus, Inc.
(301) 838-2591

Investors

Peter Vozzo
ICR Healthcare
(443) 213-0505
Email: peter.vozzo@icrhealthcare.com

Media
Diana Torres-Bixby
Burson Global
+1 917 686 0517
Email: Diana.torres-bixby@bursonglobal.com

Renk Group AG / Keyword: Mergers and Acquisitions / Sale of Business Units
Renk Group AG: RENK Enters Into Binding Agreement for the Sale of its Slide Bearings Business to Miba AG
22. Oct 2026 / 01:39 CET/CEST

Disclosure of an inside information acc. to Article 17 of the Regulation (EU) No 596/2014, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

Augsburg, October 22, 2026 – RENK Group AG, through its wholly-owned subsidiary RENK GmbH, today entered into a binding agreement for the sale of the Slide Bearings business to Miba AG from Austria.

The products of the Slide Bearings business unit include standardized slide bearings for electric motors, generators, and pumps, and are used primarily in industrial and civilian markets. With the sale of the Slide Bearings business, RENK is implementing the sector strategy it announced at the end of 2025 and is aligning its strategic focus even more consistently with the defence business. The agreed purchase price is in the low to mid three-digit million range and confirms the carrying value of the divested business.

The transaction is subject to the standard official approvals.

As a result of the sale, the Slide Bearings business unit will be reported as a discontinued operation in accordance with IFRS 5 beginning in the fourth quarter of 2026. The RENK Group will therefore report its guidance in the future exclusively on the basis of continuing operations. These include the Vehicle Mobility Solutions (VMS) and Marine & Industry (M&I) divisions. This results in the following updated guidance for the fiscal year 2026 for revenue in the amount of EUR ~1.4 billion and for adjusted EBIT from EUR 240 million to EUR 255 million.

End of Inside Information

---

GlobeNewswire Distribution Services include regulatory announcements, financial/corporate news and press releases.
Archive at www.globenewswire.com

---